Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | https://doi.org/10.5281/zenodo.16640959 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of phosphatases up-regulated and differentially expressed in human luminal B breast cancer, PNKP, as a catalytically available phosphatase and candidate therapeutic target for the adjunctive medical treatment of luminal B breast cancer. </p>